New England Journal of Medicine October 01, 2020

Early Rhythm-Control Therapy in Patients with Atrial Fibrillation

Paulus Kirchhof, A. John Camm, Andreas Goette, Axel Brandes, Lars Eckardt, Arif Elvan, et al.

Bottom Line

The EAST-AFNET 4 trial demonstrated that initiating early rhythm-control therapy in patients with recently diagnosed atrial fibrillation and cardiovascular conditions significantly reduced the composite risk of cardiovascular death, stroke, or hospitalization compared to usual care.

Key Findings

1. The primary composite outcome (cardiovascular death, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome) occurred less frequently in the early rhythm-control group (3.9 per 100 person-years) compared to the usual care group (5.0 per 100 person-years), with a hazard ratio of 0.79 (95% CI, 0.66 to 0.94; P=0.005).

2. The secondary primary outcome of mean nights spent in the hospital per year did not differ significantly between the groups (5.8 days with early rhythm control vs. 5.1 days with usual care; P=0.23).

3. Individual components of the primary outcome trended in favor of early rhythm control, including cardiovascular death (1.0% vs. 1.3% per 100 person-years) and stroke (0.6% vs. 0.9% per 100 person-years).

4. Adverse events related to rhythm-control therapy occurred in 4.9% of the early rhythm-control patients compared to 1.4% in the usual-care group, though the overall primary safety outcome (composite of death, stroke, or serious adverse events related to rhythm-control therapy) did not differ significantly (16.6% vs. 16.0%).

5. At 2 years, 82.1% of patients in the early rhythm-control group were in sinus rhythm compared to 60.5% in the usual care group.

Study Design

Design

RCT

Open-Label, Blinded-Endpoint

Sample

2,789

Patients

Duration

5.1 yr

Median

Setting

11 European countries

Population Adults with early atrial fibrillation (diagnosed within 1 year before enrollment) and concomitant cardiovascular conditions (age >75, prior TIA/stroke, or fulfilling two other cardiovascular risk criteria).

Intervention Early rhythm-control therapy comprising antiarrhythmic drugs, catheter ablation, and/or cardioversion initiated early after randomization to maintain sinus rhythm.

Comparator Usual care, consisting primarily of rate-control therapy, with rhythm control reserved only for patients experiencing severe symptoms despite adequate rate control.

Outcome A composite of cardiovascular death, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome.

Study Limitations

• The trial utilized an open-label design (PROBE), which can introduce treatment and reporting bias, although the clinical endpoints were adjudicated by a blinded committee.

• The study was stopped early (after 75% enrollment with a median 5.1 years follow-up) due to efficacy, which has the potential to overestimate the true magnitude of the treatment effect.

• The trial was specifically powered to compare broad strategies (early rhythm control vs. usual care) rather than individual rhythm-control modalities, meaning the relative efficacy of specific antiarrhythmic drugs versus catheter ablation within the early control arm remains undefined.

• The cohort specifically consisted of patients with early atrial fibrillation (diagnosed within 1 year) who had concomitant cardiovascular risk factors; therefore, these results cannot be reliably extrapolated to patients with long-standing persistent AF or young patients with lone AF.

Clinical Significance

EAST-AFNET 4 fundamentally shifted clinical practice guidelines by demonstrating that rhythm control is not merely for symptomatic relief, but provides prognostic cardiovascular benefits when implemented early in the disease course. It suggests a critical 'window of opportunity' in the first year after AF diagnosis to intervene before permanent atrial remodeling occurs, altering a two-decade-old paradigm that rate and rhythm control were prognostically equivalent.

Historical Context

The landmark AFFIRM trial (2002) and RACE trial established that in a general population of older adults with established atrial fibrillation, rhythm-control strategies offered no survival benefit over rate control and were associated with higher drug toxicity. Consequently, for nearly two decades, rate control became the default initial strategy, with rhythm control reserved strictly for patients who remained symptomatic. Since AFFIRM, catheter ablation technology rapidly advanced, safer use of antiarrhythmic drugs evolved, and observational data suggested earlier intervention might prevent atrial remodeling. EAST-AFNET 4 successfully tested this modern 'early rhythm control' hypothesis, overturning previous dogmas by identifying a specific patient population (early AF) that derives hard outcome benefits from pursuing sinus rhythm.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the concept of atrial remodeling explain why early rhythm control in the EAST-AFNET 4 trial was more effective at preventing adverse cardiovascular outcomes compared to the delayed or symptom-driven rhythm control seen in older landmark trials like AFFIRM?

Key Response

This tests foundational pathophysiology. Atrial fibrillation begets atrial fibrillation through progressive structural and electrical remodeling. Early intervention interrupts this cycle, preserving atrial function and reducing long-term thromboembolic and heart failure risks, whereas older trials intervened later in the disease process when irreversible remodeling had already occurred.

Resident

A 65-year-old asymptomatic patient with newly diagnosed atrial fibrillation, hypertension, and diabetes presents to the clinic. Based on EAST-AFNET 4, how would your management strategy differ from the traditional rate-control-first approach, and what specific modalities could you offer?

Key Response

Residents must translate this paradigm shift into practice. Traditionally, an asymptomatic patient would receive rate control. Post-EAST-AFNET 4, early rhythm control (via antiarrhythmic drugs or ablation) should be actively discussed and offered even in asymptomatic patients to improve long-term cardiovascular outcomes.

Fellow

In EAST-AFNET 4, a significant proportion of the early rhythm control group was managed with antiarrhythmic drugs rather than upfront catheter ablation. How should electrophysiologists interpret this when counseling patients about the choice of rhythm control modality, especially when integrating findings from trials like EARLY-AF?

Key Response

Fellows need to integrate multiple studies. While EAST-AFNET 4 proves the strategy of early rhythm control improves outcomes, it does not mandate upfront ablation. Fellows must weigh this against EARLY-AF, which showed upfront cryoablation was superior to antiarrhythmic drugs for maintaining sinus rhythm, to offer nuanced patient-centered care.

Attending

The EAST-AFNET 4 trial was stopped early for efficacy after a median follow-up of 5.1 years. How do you balance the ethical obligation of early trial stoppage against the risk of implementing a systemic practice change based on potentially exaggerated treatment effects, and how do you incorporate this into your teaching on critical appraisal?

Key Response

Attendings must critically evaluate practice-changing data. Truncated trials can sometimes exaggerate benefits. However, teaching points should emphasize that the robust sample size, long median follow-up prior to stopping, and biologic plausibility provide confidence that the paradigm shift toward early rhythm control is robust.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

EAST-AFNET 4 utilized a PROBE (Prospective Randomized Open, Blinded Endpoint) design. Given the unblinded treatment allocation, how might performance bias or co-intervention bias have influenced the primary composite outcome, and is blinded endpoint adjudication sufficient to mitigate these methodological threats?

Key Response

PROBE designs are practical but risk performance bias if the rhythm control group receives more intensive general cardiovascular care or closer follow-up. Methodologists must evaluate if the blinded adjudication of hard endpoints (like death and stroke) adequately protects the trial internal validity against unblinded care differences.

Journal Editor

As a statistical reviewer evaluating this manuscript, how would you critically appraise the broad pragmatic definition of early AF (diagnosed within 1 year) combined with diverse cardiovascular comorbidities, and what subgroup analyses would you demand to ensure the treatment effect is not driven solely by a specific phenotype like heart failure?

Key Response

Editors focus on whether the broad pragmatic enrollment masks critical subgroup interactions. A tough reviewer would scrutinize the heterogeneity of the population to ensure the overarching conclusion of early rhythm control applies universally, rather than being disproportionately driven by patients with specific conditions like reduced ejection fraction.

Guideline Committee

Historically, AF guidelines positioned rhythm control strictly for symptom amelioration (Class I). Based on the results of EAST-AFNET 4, what specific Class of Recommendation and Level of Evidence should be assigned to early rhythm control for asymptomatic patients with newly diagnosed AF, and how does this alter the fundamental goals of AF management?

Key Response

Guideline committee members must translate evidence into formal recommendations. EAST-AFNET 4 prompted major updates, such as the 2023 ACC/AHA/ACCP/HRS guidelines upgrading early rhythm control to a Class 2a recommendation for reducing cardiovascular outcomes in patients with recently diagnosed AF, explicitly shifting the therapeutic goal beyond mere symptom relief.

Clinical Landscape

Noteworthy Related Trials

2002

AFFIRM Trial

n = 4,060 · NEJM

Tested

Rhythm-control strategy (antiarrhythmic drugs and cardioversion)

Population

Patients aged 65 years or older or with risk factors for stroke or death with atrial fibrillation

Comparator

Rate-control strategy

Endpoint

Overall mortality

Key result: There was no survival advantage with the rhythm-control strategy compared to the rate-control strategy, and rhythm control had more adverse drug effects.

2002

RACE Trial

n = 522 · NEJM

Tested

Rhythm-control strategy (serial cardioversions and antiarrhythmic drugs)

Population

Patients with persistent atrial fibrillation after previous electrical cardioversion

Comparator

Rate-control strategy

Endpoint

Composite of cardiovascular death, heart failure, thromboembolic complications, bleeding, pacemaker implantation, or severe adverse drug effects

Key result: Rate control was non-inferior to rhythm control for preventing cardiovascular morbidity and mortality.

2019

CABANA Trial

n = 2,204 · JAMA

Tested

Catheter ablation (rhythm control)

Population

Patients with new-onset or undertreated atrial fibrillation requiring therapy

Comparator

Medical therapy (rate or rhythm control drugs)

Endpoint

Composite of death, disabling stroke, serious bleeding, or cardiac arrest

Key result: Catheter ablation did not significantly reduce the primary composite endpoint compared with medical therapy in the intention-to-treat analysis, though it reduced AF recurrence.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis